Merkel cell carcinoma: current status of targeted and future potential for immunotherapies

被引：9

作者：

Aldabagh, Bishr ^{[1
]}

Joo, Jayne ^{[2
]}

Yu, Siegrid S. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA

[2] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA

来源：

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2014年 / 33卷 / 02期

关键词：

GROWTH-FACTOR RECEPTOR; SMALL T-ANTIGEN; POLYOMAVIRUS INFECTION; GENE-THERAPY; TUMOR; EXPRESSION; SURVIVAL; METASTASES; PROGNOSIS; CANCER;

D O I：

10.12788/j.sder.0084

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Merkel cell carcinoma is an aggressive neuroendocrine tumor with a high incidence of local recurrence, regional nodal and distant metastasis, and a high mortality rate. It has been linked to a polyomavirus in addition to immune suppression. Traditionally, treatment options have been limited to surgery and radiation therapy. Better understanding of the molecular pathways of infection and carcinogenesis has provided potential molecular targets and potential immunotherapies which are discussed in this review. (C) Frontline Medical Communications

引用

页码：76 / 82

页数：7

共 88 条

[1] T-cell receptor gene therapy of established tumors in a murine melanoma model [J].

Abad, John D. ;

Wrzensinski, Claudia ;

Overwijk, Willem ;

De Witte, Moniek A. ;

Jorritsma, Annelies ;

Hsu, Cary ;

Gattinoni, Luca ;

Cohen, Cyrille J. ;

Paulos, Chrystal M. ;

Palmer, Douglas C. ;

Haanen, John B. A. G. ;

Schumacher, Ton N. M. ;

Rosenberg, Steven A. ;

Restifo, Nicholas P. ;

Morgan, Richard A. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (01) :1-6

[2] Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers [J].

Afanasiev, Olga K. ;

Yelistratova, Lola ;

Miller, Natalie ;

Nagase, Kotaro ;

Paulson, Kelly ;

Iyer, Jayasri G. ;

Ibrani, Dafina ;

Koelle, David M. ;

Nghiem, Paul .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5351-5360

[3] Epidemiology of primary Merkel cell carcinoma in the United States [J].

Agelli, M ;

Clegg, LX .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :832-841

[4] Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study [J].

Albores-Saavedra, Jorge ;

Batich, Kristen ;

Chable-Montero, Freddy ;

Sagy, Noa ;

Schwartz, Arnold M. ;

Henson, Donald Earl .

JOURNAL OF CUTANEOUS PATHOLOGY, 2010, 37 (01) :20-27

[5] Merkel cell carcinoma: Prognosis and treatment of patients from a single institution [J].

Allen, PJ ;

Bowne, WB ;

Jaques, DP ;

Brennan, MF ;

Busam, K ;

Coit, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2300-2309

[6] Merkel Cell Carcinoma Histologic Features and Prognosis [J].

Andea, Aleodor A. ;

Coit, Daniel G. ;

Amin, Bijal ;

Busam, Klaus J. .

CANCER, 2008, 113 (09) :2549-2558

[7]

Ang KK, 2002, CANCER RES, V62, P7350

[8]

[Anonymous], 2013, ADV LOW INT GRAD NEU

[9] Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma [J].

Aoyama, Yumiko ;

Kaibara, Atsunori ;

Takada, Akitsugu ;

Nishimura, Tetsuya ;

Katashima, Masataka ;

Sawamoto, Taiji .

INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :443-451

[10] Survivin Is a Therapeutic Target in Merkel Cell Carcinoma [J].

Arora, Reety ;

Shuda, Masahiro ;

Guastafierro, Anna ;

Feng, Huichen ;

Toptan, Tuna ;

Tolstov, Yanis ;

Normolle, Daniel ;

Vollmer, Laura L. ;

Vogt, Andreas ;

Doemling, Alexander ;

Brodsky, Jeffrey L. ;

Chang, Yuan ;

Moore, Patrick S. .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (133)

← 1 2 3 4 5 6 7 8 9 →